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A B S T R A C T
Background: Randomized trials with antidepressants are often run under double blind placebo-controlled
conditions, whereas those with psychotherapies are mostly unblinded. This can introduce bias in favor of
psychotherapy when the treatments are directly compared. In this meta-analysis, we examine this
potential source of bias.
Methods: We searched Pubmed, PsycInfo, Embase and the Cochrane database (1966 to January 2014) by
combining terms indicative of psychological treatment and depression, and limited to randomized trials.
We included 35 trials (with 3721 patients) in which psychotherapy and pharmacotherapy for adult
depression were directly compared with each other. We calculated effect sizes for each study indicating
the difference between psychotherapy and pharmacotherapy at post-test. Then, we examined the
difference between studies with a placebo condition and those without in moderator analyses.
Results: We did not ﬁnd a signiﬁcant difference between the studies with and those without a placebo
condition. The studies in which a placebo condition was included indicated no signiﬁcant difference
between psychotherapy and pharmacotherapy (g = 0.07; NNT = 25). Studies in which no placebo
condition was included (and patients and clinicians in both conditions were not blinded), resulted in a
small, but signiﬁcant difference between psychotherapy and pharmacotherapy in favor of pharmaco-
therapy (g = 0.13; NNT = 14).
Conclusions: Studies comparing psychotherapy and pharmacotherapy in which both groups of patients
(and therapists) are not blinded (no placebo condition is included) result in a very small, but signiﬁcantly
higher effect for pharmacotherapy.
 2015 Published by Elsevier Masson SAS.
Contents lists available at ScienceDirect
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When assessing and comparing the outcomes of psychological
and pharmacological antidepressant treatments, there is a
fundamental problem regarding blinding of patients and thera-
pists. In trials comparing psychotherapy to control conditions,
patients randomized to psychotherapy typically know whether
they have been randomized to the psychotherapeutic interven-
tion or to the control condition, and the same is true for the
treating therapists [26,28,54]. This may result in expectations of* Corresponding author. Department of Clinical Psychology, VU University
Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.
Tel.: +31 20 5988757; fax: +31 20 5988758.
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Please cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), http
http://dx.doi.org/10.1016/j.eurpsy.2015.06.005
0924-9338/ 2015 Published by Elsevier Masson SAS.positive effects and hope in the psychological intervention in
patients, therapists and researchers, and increases in frustration
and despair (nocebo effects) [28] in the patients in the control
condition, inﬂating the effect sizes of psychotherapy [26,59].
These biases are likely to be especially large in studies with
waiting lists or care-as-usual control conditions. It is not
surprising therefore that the effect sizes of psychotherapy studies
are especially large when compared to waiting list controls
[47,48].
In contrast, for treatment with antidepressants, blinding of both
patients and therapists is possible in principle, and hope induction,
activation and other unspeciﬁc factors inﬂuencing outcome can be
controlled. As a consequence, the effect size of antidepressants
may to be underestimated compared to those of psychotherapy
because the fact that patients know about the risk to receiveing on the outcomes of psychotherapy and pharmacotherapy for
://dx.doi.org/10.1016/j.eurpsy.2015.06.005
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treatment. However, it has also been questioned whether typical
trials on antidepressants are blinded properly, because usually
inert placebos are used instead of active placebos, resulting in
many patients who know to which condition they have been
assigned [22,35,49].
If this is true, the effects of hope induction and expectancies in
patients, clinicians and researchers should be larger in placebo-
controlled trials with two active treatments compared to that with
one because the chance to get an active treatment is larger. This is
supported by a meta-analysis which revealed that placebo
response is higher in studies with two active treatments (44,8%)
compared to those with one only (34,3%) [63]. The authors also
report that the response rate to the antidepressants declined with
increasing risk to get placebo only (66,5% with two active drugs
without placebo, 55,7% with two active drugs and placebo, 51,7
with one active and one placebo arm). Similar results have been
reported by another meta-analysis [64].
A consequence of the effects discussed above is that meta-
analytic comparisons of efﬁcacy between psychotherapy and
pharmacotherapy may overestimate effects of psychotherapy and
underestimate those of pharmacotherapy if a placebo-control
group is included [1]. If no placebo control group is included,
patients, therapists and researchers in both psychotherapy and
pharmacotherapy are not blinded, and the advantage of psycho-
therapy over pharmacotherapy should not be expected here.
Our earlier meta-analyses of studies directly comparing
psychotherapy and pharmacotherapy typically show that there
are no signiﬁcant differences between the two [13,14]. If blinding
indeed affects outcome, one could expect a difference between
studies with and without a placebo control condition. This
question has not been examined in earlier meta-analyses of
studies directly comparing psychotherapy and pharmacotherapy.
We therefore decided to perform a new meta-analysis of
studies directly comparing psychotherapy and pharmacotherapy
for adult depression, and to examine whether studies that also
included a placebo condition (blinded pharmacotherapy) differed
signiﬁcantly from the studies in which no placebo condition was
included (unblinded pharmacotherapy).
2. Methods
2.1. Identiﬁcation and selection of studies
This meta-analysis was conducted according to the PRISMA
guidelines [39]. We used a database of papers on the psychological
treatment of depression that has been described in detail
elsewhere [12], and that has been used in a series of earlier
published meta-analyses (http://www.evidencebasedpsycho
therapies.org). This database has been continuously updated
through comprehensive literature searches (covering studies
published between 1966 to January 2014). In these searches, we
examined 14,902 abstracts from Pubmed, PsycInfo, Embase and
the Cochrane Register of Trials. These abstracts were identiﬁed by
combining terms indicative of psychological treatment and
depression (both MeSH terms and text words). The searches were
usually conducted by two independent researchers, but some of
the yearly updates were done by only one researcher. Thus, a
biased study selection cannot be completely excluded. For
this database, we also checked the primary studies from earlier
meta-analyses of psychological treatment for depression to
ensure that no published studies were missed (http://www.
evidencebasedpsychotherapies.org). From the 14,902 abstracts,
we retrieved 1613 full-text papers for possible inclusion in the
database.Please cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), httpWe included (a) randomized trials (b) in which the effects of a
psychological treatment (c) was directly compared with the effects
of antidepressant medication (d) in adults (e) with a depressive
disorder. We included studies with and without a pill placebo
condition, but in order to keep the comparison between blinded
and not-blinded studies as clear as possible, we excluded studies in
which another type of control condition was used (such as care-as-
usual or relaxation).
Only studies in which subjects met diagnostic criteria for the
disorder according to a structured diagnostic interview (such as
the SCID, CIDI, or MINI) were included. Comorbid mental or
somatic disorders were not used as an exclusion criterion. Studies
on inpatients, adolescents and children (below 18 years of age)
were also excluded. We further excluded maintenance studies,
aimed at people who had already recovered or partly recovered
after an earlier treatment. Language was not used as an exclusion
criterion.
2.2. Quality assessment and data extraction
We assessed the validity of included studies using four criteria
of the ‘‘Risk of bias’’ assessment tool, developed by the Cochrane
Collaboration [29]. This tool assesses possible sources of bias in
randomized trials, including the adequate generation of allocation
sequence; the concealment of allocation to conditions; the
prevention of knowledge of the allocated intervention (masking
of assessors); and dealing with incomplete outcome data (this was
assessed as positive when intention-to-treat analyses were
conducted, meaning that all randomized patients were included
in the analyses).
We also coded additional aspects of the included studies,
including participant characteristics (recruitment method: com-
munity, from clinical samples, or other; target group: adults in
general, or more speciﬁc target groups such as older adults),
intervention characteristics (format: individual, group, or guided
self-help; number of sessions; type of psychotherapy: cognitive
behavior therapy, interpersonal psychotherapy, or other type; type
of medication: SSRI, TCA, or other); and study characteristics
(country: United States or other).
2.3. Meta-analyses
For each comparison between a psychotherapy and a pharma-
cotherapy condition, the effect size indicating the difference
between the two groups at post-test was calculated (Hedges’s g).
Effect sizes were calculated by subtracting (at post-test) the
average score of the psychotherapy group from the average score
of the pharmacotherapy group, and dividing the result by the
pooled standard deviation. Because some studies had relatively
small sample sizes, we corrected the effect size for small sample
bias [25].
In the calculations of effect sizes, we used only those
instruments that explicitly measured symptoms of depression. If
means and standard deviations were not reported, we used the
procedures of the Comprehensive Meta-analysis software (see
below) to calculate the effect size using dichotomous outcomes;
and if these were not available either, we used other statistics
(such as t-value or P-value) to calculate the effect size. To calculate
pooled mean effect sizes, we used the computer program
Comprehensive Meta-Analysis (version 2.2.021; CMA).
We tested whether the effect sizes of the studies with a
placebo condition differed from the effect sizes of the studies
without placebo with a mixed effects model. In this mixed
effects model, studies within subgroups were pooled with the
random effects model, while tests for signiﬁcant differences
between subgroups were conducted with the ﬁxed effects modeling on the outcomes of psychotherapy and pharmacotherapy for
://dx.doi.org/10.1016/j.eurpsy.2015.06.005
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the formulae provided by Kraemer and Kupfer [36]. The NNT
indicates the number of patients that have to be treated in order
to generate one additional positive outcome [37].
In all analyses, we calculated the I2-statistic as an indicator of
heterogeneity in percentages. A value of 0% indicates no observed
heterogeneity, and larger values indicate increasing heterogeneity,
with 25% as low, 50% as moderate, and 75% as high heterogeneity
[30]. We calculated 95% conﬁdence intervals around I2 [32], using
the non-central Chi2-based approach within the heterogi module
for Stata [55].
We tested for publication bias by inspecting the funnel plot on
primary outcome measures and by Duval and Tweedie’s trim and
ﬁll procedure [19], which yields an estimate of the effect size after
the publication bias has been taken into account (as implemented
in CMA). We also conducted Egger’s test of the intercept to quantify
the bias captured by the funnel plot and test whether it was
signiﬁcant.
Multivariate metaregression analyses were conducted with
the effect size as the dependent variable. To decide which
variables should be entered as predictors in the regression
model, we ﬁrst deﬁned a reference group within each category
of variables. To avoid collinearity among the predictors of
the regression model, we ﬁrst examined whether high correla-
tions were found among the variables that could be entered
into the model. Next, we calculated the correlations between
all predictors (except the reference variables). Because no
correlations were higher than r = 0.50, all predictors could be
entered in the regression models. Multivariate regression
analyses were conducted in STATA MP, version 11 for Mac
(Statacorp).Fig. 1. Flowchart of inc
Please cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), http3. Results
3.1. Selection and inclusion of studies
After examining a total of 14,902 abstracts (10,992 after
removal of duplicates), we retrieved 1613 full-text papers for
further consideration. We excluded 1578 of the retrieved papers.
The reasons for excluding studies are given in Fig. 1. Thirty-ﬁve
studies met inclusion criteria [2–4,5,6,8,15–18,20,21,24,27,31,
33,34,40–43,45,46,50–53,56–58,60–62,65,66]. Fig. 1 presents a
ﬂowchart describing the inclusion process. These 35 studies were
all included in our larger meta-analysis of direct comparisons of
psychotherapy and pharmacotherapy for depression and anxiety
disorders [14] (except one study that was published after the
deadline for inclusion in that meta-analysis) [42].
3.2. Characteristics of included studies
Selected characteristics of the included 35 studies are presented
in Table 1. In these studies, 3721 patients were included, 1962 in
the psychotherapy conditions, 1759 in the pharmacotherapy
conditions. Nine studies included a placebo control condition,
26 studies did not. In six studies, two different types of
psychotherapy were examined (and compared with pharmaco-
therapy), resulting in 41 comparisons between a psychotherapy
and pharmacotherapy condition (10 comparisons with placebo,
31 without).
Sixteen studies recruited patients (partly) through the commu-
nity, 15 exclusively from clinical samples, and three used other
methods (one did not report the recruitment method). Twenty-
nine studies were aimed at adults in general, three on older adults,lusion of studies.
ing on the outcomes of psychotherapy and pharmacotherapy for
://dx.doi.org/10.1016/j.eurpsy.2015.06.005
Table 1
Selected characteristics of studies directly comparing psychotherapy and pharmacotherapy for adult depression.
Recr Target
group
Depression Psychotherapy N psy N sess Format Pharmacotherapy N pha Pla FU paper Pha fu Long-term
outcome
FU Qualitya Country
Barber et al., 2012 [2] Comm Adults MDD DYN 51 20 Ind Mix/Oth 55 + No FU   + + US
Barrett et al., 2001 [3] Clin Adults Mood PST 80 6 Ind SSRI 80 + No FU + + + + US
Bedi et al., 2000 [4] Clin Adults MDD Couns 39 NR Ind Mix/Oth 44  No FU + +   EU
Blackburn et al., 1981 [5] Comm Adults MDD CBT 7 15 Grp TCA 9  Blackburn, 1986 N Rel 24     US
Blackburn and Moore 1997 [6] Clin Adults MDD CBT 24 16 Ind Mix/Oth 43  No FU    + EU
Browne et al., 2002 [8] Comm Adults DYS IPT 122 10 Ind SSRI 117  No FU + + +  CA
David et al., 2008 [15] Comm Adults MDD CBT 56 20 Ind SSRI 57  David, 2008 Y Rel/Rem 6   + + EU
REBT 57 20 Ind David, 2008 Y Rel/Rem 6
Dekker et al., 2008 [16] Clin Adults MDD DYN 59 16 Ind Mix/Oth 44  No FU   +  EU
Dunlop et al., 2012 [17] Comm Adult MDD CBT 41 16 Ind SSRI 39  No FU + + + + US
Dunner et al., 1996 [18] NR Adults DYS CBT 9 16 Ind SSRI 11  No FU   +  US
Elkin et al., 1989 [20] Clin Adults MDD IPT 61 16 Ind TCA 57 + Shea, 1992 N Rel/Rec 18 + + + + US
CBT 59 16 Ind Shea, 1992 N Rel/Rec 18
Finkenzeller et al., 2009 [21] Other Stroke patients MDD IPT 23 12 Grp SSRI 24  No FU +  + + EU
Frank et al., 2011 [24] Clin Adults MDD IPT 160 12 Ind SSRI 158  No FU   + + US
Hegerl et al., 2010 [27] Clin Adults Mood CBT 52 10 Grp SSRI 76 + No FU + + + + EU
Hollon et al., 1992 [31] Clin Adults MDD CBT 25 20 Ind TCA 57  Evans, 1992 N Rel 24   + + US
Jarrett et al., 1999 [33] Comm Adults MDD CBT 36 20 Ind MAOI 36 + No FU + + + + US
Keller et al., 2000 [34] Clin Chronic MDD CBASP 226 18 Ind SNRI 220  No FU + + + + US
Markowitz et al., 2005 [40] Comm Adults DYS IPT 23 17 Ind SSRI 24  No FU   + + US
Couns 26 17 Ind No FU
Marshall et al., 2008 [41] Comm Adults MDD CBT 37 16 Ind Mix/Oth 30  No FU     CA
IPT 35 16 Ind No FU
Martin et al., 2001 [42] Comm Adults MDD IPT 13 16 Ind SNRI 15  No FU    + EU
McBride et al., 2007 [43] Comm Adults MDD CBT 21 16 Ind Mix/Oth 21  No FU     CA
McKnight et al., 1992 [45] Comm Adults MDD CBT 12 8 Ind TCA 11  No FU     US
Mohr et al., 2001 [46] Other MS patients MDD CBT 20 16 Ind SSRI 15  Mohr, 2001 N Bdi/Hamd 6    + US
Supp Ex 19 16 Grp Mohr, 2001 N Bdi/Hamd 6
Moradveisi et al., 2013 [50] Comm Adults MDD BAT 50 16 Ind SSRI 50  Moradvesi, 2013 N Rel/Rem/Resp 12 + + + + Iran
Murphy et al., 1984 [51] Clin Adults MDD CBT 24 20 Ind TCA 24  Simons, 1986 N Rel/Resp 12 + +  + US
Mynors-Wallis et al., 1995 [53] Clin Adults MDD PST 29 6 Ind TCA 27 + No FU  + + + + EU
Mynors-Wallis et al., 2000 [52] Clin Adults MDD PST gp 39 6 Ind SSRI 36  Mynors-Wallis, 2000 N Rec 12 + + + + EU
PST n 41 6 Ind Mynors-Wallis, 2000 N Rec 12
Ravindran et al., 1999 [56] Comm Adults DYS CBT 24 12 Grp SSRI 22 + No FU  + + +  CA
Reynolds et al., 1999 [57] Comm Elderly MDD IPT 16 16 Ind TCA 25 + No FU    + + US
Rush et al., 1977 [58] Clin Adults MDD CBT 19 20 Ind TCA 22  No FU    + + US
Salminen et al., 2008 [60] Clin Adults MDD DYN 26 16 Ind SSRI 25  No FU     + EU
Shamsaei et al., 2008 [61] Clin Adults MDD CBT 40 8 Ind SSRI 40  No FU  +  +  Iran
Sharp et al., 2010 [62] Other PPD Mood Couns 112 6 Ind Mix/Oth 106  No FU  + + + + EU
Thompson et al., 2001 [65] Comm Elderly MDD CBT 36 18 Ind TCA 33  No FU     + US
Williams et al., 2000 [66] Comm Elderly Mood PST 113 6 Ind SSRI 106 + No FU  + + + + US
BAT: behavioral activation therapy; CA: Canada; CBASP: cognitive behavioral analysis system of psychotherapy; CBT: cognitive behavior therapy; Clin: recruitment from clinical samples only; Comm: (part of the) sample recruited
from the community; Couns: non-directive supportive counseling; DYN: psychodynamic therapy; DYS: dysthymic disorder; EU: Europe; Grp: group format; Ind: individual format; IPT: interpersonal psychotherapy; Maoi:
Monoamine oxidase inhibitor; MDD: major depressive disorder; Mix/oth: other antidepressant/mix of antidepressants or protocolized treatment with antidepressants; Mood: mixed mood disorder; MS: multiple sclerosis; N sess:
number of sessions; Npha: number of patients in the pharmacotherapy conditions; Npsy: number of patients in the psychotherapy condition; NR: not reported; PPD: post-partum depression; PST gp: PST by a general practitioner;
PST n: PST by a nurse; PST: problem-solving therapy; REBT: rational emotive behavior therapy; Recr: recuitment; Snri: Serotonin–norepinephrine reuptake inhibitor; Ssri: selective serotonin reuptake inhibitor; Supp Ex: supportive-
expressive therapy; Tca: tricyclic antidepressant; US: United States.
a In this column, a positive or negative sign is given for four quality criterias, respectively: allocation sequence; concealment of allocation to conditions; blinding of assessors; and intention-to-treat analyses.
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depression, multiple sclerosis patients, and stroke patients). Most
studies (27) were aimed at patients with a major depressive
disorder, four were aimed at unipolar mood disorders in general,
and four were exclusively aimed at patients with dysthymia. Of the
41 psychotherapies that were examined, 19 were cognitive
behavior therapy, eight interpersonal psychotherapy, ﬁve prob-
lem-solving therapy, four non-directive counseling, three psycho-
dynamic therapy and two others. Thirty-six delivered the
treatment in an individual format and ﬁve in group format. The
number of treatment sessions ranged from 6 to 20 (in 26 compar-
isons, the number of sessions ranged from 16 to 20). In 16 of the
35 studies, a SSRI was used, nine used a TCA, and the remaining
10 used another medication (MAOI, SNRI) or a protocol with a mix
of medications. Eighteen studies were conducted in the US, 11 in
Europe, 4 in Canada, and 2 in Iran.
The quality of the included studies varied. Seventeen of the
35 studies reported an adequate sequence generation. Fifteen
studies reported allocation to conditions by an independent (third)
party. Twenty-four studies reported blinding of outcome assessors
and in 25 studies, intention-to-treat analyses were conducted.
Eleven studies met all four-quality criteria, 13 met 2 or 3 criteria;
and the remaining 11 studies had a lower quality (0 or 1 of the
4 criterias).
3.3. Difference between studies with and without a placebo condition
The overall effect size indicating the difference between
psychotherapy and pharmacotherapy in all studies (regardless
of the presence of a placebo control condition) was non-signiﬁcant
with g = 0.07 (95% CI: 0.210.07; NNT = 25) in favor of
pharmacotherapy (I2 = 37%; 95% CI: 157), which is very much
in line with earlier meta-analyses of studies directly comparing
psychotherapy with pharmacotherapy [13,14].
When we compared studies with and without a placebo
condition, we found no signiﬁcant differences (P = 0.15). The
10 comparisons between psychotherapy and pharmacotherapy
with a placebo condition resulted in a non-signiﬁcant effect size of
g = 0.02 (95% CI: 0.150.18), with zero heterogeneity (I2 = 0; 95%
CI: 0–62). This corresponds with a NNT of 83. The results are
summarized in Table 2 and in Fig. 2. The 31 comparisons in which
no placebo control condition was used resulted, in line with the
hypothesis, in a small, but signiﬁcant effect in favor of pharmaco-
therapy with g = 0.13 (95% CI: 0.230.03; NNT = 14) with
moderate heterogeneity (I2 = 43; 95% CI: 1363).Table 2
Effects of studies comparing psychotherapy and pharmacotherapy for adult depression
With placebo control 
Ncomp g 95% CI I
2 95%
All studies 10 0.02 0.150.18 0 06
One outlier removed [58] 10 0.01 0.150.16 0 06
One effect size per study (only highest) 9 0.03 0.140.21 0 06
One effect size per study (only lowest) 9 0.02 0.160.20 0 06
Only HAM-D 5 0.05 0.300.21 0 07
Sensitivity analyses
Only high-quality studies 7 0.04 0.180.11 0 07
No combined treatment condition
in study
8 0.04 0.180.09 0 06
Only SSRI’s 4 0.03 0.170.21 0 08
Only CBT 4 0.01 0.260.27 0 08
Studies on dysthymia excluded 9 0.01 0.180.15 0 06
Studies aimed at adults in general 8 0.03 0.210.15 0 06
CI: conﬁdence interval; Ncomp: number of comparisons.
a According to the random effects model.
b The P-values in this column indicate whether the difference between the effect sizes i
signiﬁcant.
Please cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), httpThere was one study that could be considered as an outlier,
because the 95% CI around the effect size did not overlap with the
95% CI of the pooled effect size [58]. After removal of this outlier,
the difference between the studies with a placebo condition and
those without, approached signiﬁcance (P = 0.09; g = 0.15;
NNT = 12).
In the analyses, we included six studies in which two
psychological treatments were compared with the same pharma-
cotherapy group. This means that multiple comparisons from these
studies were included in the same analysis, that are not
independent of each other, which may have resulted in an
artiﬁcial reduction of heterogeneity and may have affected the
pooled effect size. We examined the possible effects of this by
conducting an analysis in which we included only one effect size
per study. First, we included only the comparison with the largest
effect size from these studies and then, we conducted another
analysis in which we included only the smallest effect size. As can
be seen from Table 2, the resulting effect sizes did not affect the
overall mean effect size very much, nor did it affect heterogeneity
considerably.
When we limited the analyses to the effect sizes based on the
HAM-D-17 only (Table 2), we found that the difference between
the two groups of studies became smaller.
We examined possible publication bias in the two groups of
studies separately as well as in the full sample of studies, but found
no indications that there was signiﬁcant publication bias. In the full
sample as well as in each of the two subsamples, Duvall and
Tweedie’s trim and ﬁll procedure indicated that there were no
missing studies, and the adjusted and unadjusted effect sizes were
equal. Egger’s test also did not point at signiﬁcant asymmetry of
the funnel plot for any of the samples.
3.4. Sensitivity analyses
We conducted a series of sensitivity analyses to examine the
robustness of our ﬁndings. In these analyses, we ﬁrst limited the
analyses to the studies meeting all quality criteria. Then, in another
analysis, we included only studies examining SSRI as pharmaco-
therapy, then with only studies examining CBT as psychotherapy.
Next, we excluded studies exclusively aimed at dysthymic
patients. Finally, we excluded studies aimed at speciﬁc target
groups.
In these analyses, the results of the main analyses were mostly
replicated. The difference between studies with a placebo group
did not differ signiﬁcantly from those without in any of the: Hedges’ ga.
Without placebo control
 CI NNT Ncomp g 95% CI I
2 95% CI NNT Pb
2 83 31 0.13 0.230.03 43 1363 14 0.15
2 167 30 0.15 0.250.05 33 057 12 0.09
5 63 26 0.10 0.210.01 42 864 18 0.21
5 83 26 0.12 0.240.01 47 1566 15 0.20
9 36 25 0.09 0.210.03 50 2169 20 0.75
1 45 6 0.17 0.320.02 46 079 10 0.21
8 45 18 0.18 0.280.07 22 056 10 0.12
5 63 16 0.16 0.270.04 10 047 11 0.10
5 167 15 0.04 0.120.19 31 063 45 0.85
5 167 27 0.09 0.200.02 41 663 20 0.44
8 63 25 0.14 0.260.03 39 263 13 0.32
n the group of studies with a placebo condition differs from those without placebo is
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Fig. 2. Forrest plot of studies comparing psychotherapy and pharmacotherapy for adult depression, with and without placebo control condition.
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indicated no signiﬁcant difference between psychotherapy and
pharmacotherapy (effect sizes ranged from g = 0.03 to g = 0.04).
In all analyses of the studies without placebo control group, the
difference between psychotherapy and pharmacotherapy was
signiﬁcant, with all analyses pointing at a small but signiﬁcant
difference between psychotherapy and pharmacotherapy in favor
of pharmacotherapy (effect sizes ranging from g = 0.09 to
0.17). The only exception was the subsample of studies on
CBT. In these studies, no signiﬁcant difference between psycho-
therapy and pharmacotherapy was found (g = 0.04; 95% CI:
0.120.19).
3.5. Multivariate metaregression analysis
In order to examine the possible inﬂuence of other character-
istics of the patients, the therapists, the interventions and the
studies, we conducted a multivariate metaregression analysis in
which we entered a dummy variable indicating whether or not a
placebo condition was used in the study, while adjusting for the
major characteristics of the studies.
We ﬁrst entered all variables simultaneously in the model
(Appendix 1), and found that the dummy variable indicating
whether the study had a placebo condition or not, was not
signiﬁcantly associated with the effect size (P = 0.15).
We then conducted a (manual) back-step metaregression
analysis. In this analysis, we dropped the least signiﬁcant variable
in each step, until only signiﬁcant predictors were retained in the
model (Appendix 1). The results of this parsimonious modelPlease cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), httpindicated that there was a trend (P = 0.06) indicating that studies
with a placebo condition may differ from those without a placebo
condition.
We ran these analyses once more while leaving out the
potential outlier [58]. The results were comparable to the analyses
of the full sample, except that in the parsimonious model, the
difference between studies with a placebo and those without was
borderline signiﬁcant (P = 0.06).
4. Discussion
In this meta-analysis, we examined the inﬂuence of blinding in
trials directly comparing psychotherapy and pharmacotherapy for
adult depression. We divided these studies into two groups. In the
ﬁrst group of studies, a pill placebo condition was included. In
these studies, the patients, therapists and researchers in the
pharmacotherapy conditions were blinded for whether the
patients received pharmacotherapy or placebo. In the second
group of studies, no placebo condition was included, and in these
studies, patients, therapists and researchers were not blinded for
the fact that the patients received pharmacotherapy. In both
groups of studies, the participants in the psychotherapy conditions
were not blinded for their assignment to psychotherapy. These
studies did not allow us to examine the effects of not being blinded
for psychotherapy directly, but they did enable us to test the effects
of being blinded or not in the pharmacotherapy conditions. We did
not ﬁnd a signiﬁcant difference between these groups of studies,
although the outcomes were in the expected direction. The studies
in which a placebo condition was included indicated no signiﬁcanting on the outcomes of psychotherapy and pharmacotherapy for
://dx.doi.org/10.1016/j.eurpsy.2015.06.005
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in which no placebo condition was included, however, resulted in a
small, but signiﬁcant difference between psychotherapy and
pharmacotherapy in favour of pharmacotherapy.
These results could suggest that in the acute treatment of
depression, pharmacotherapy is somewhat more effective than
psychotherapy, and this may be a reason for clinicians and patients
to prefer pharmacotherapy over psychotherapy. Although the
difference is signiﬁcant, it is also small, however, as effect sizes of
d < 0.20 are usually considered to be small [9]. There is no generally
accepted threshold for what a clinically signiﬁcant effect is, with
some suggesting that an effect size of d = 0.5 may be such a threshold
[23]. But it has also been suggested that this threshold is indeed
lower (d = 0.24) [11]. The effect sizes found in this paper are all very
small and probably can not be considered to be clinically relevant.
But the results of this study do indicate that blinding in the
pharmacotherapy conditions reduces the effects and makes it
probable that the effects of psychotherapies, which can not be
blinded properly [26,54], are also in part the result of the hope and
expectations in patients, therapists and researchers related to
knowing that they are assigned to an active treatment. Earlier
meta-analyses of direct comparisons between psychotherapy and
pharmacotherapy have not examined the effects of the presence of
a placebo condition on the differential effects of the two
treatments [13,14].
The best way to assess clinical signiﬁcance for the relative
effects of psychotherapy and pharmacotherapy, so when they are
directly compared with each other, is probably when they are both
not blinded for therapists and patients (so no placebo condition is
included), but use blinded raters. This means that the effects of
blinding are not present in both conditions, and the exact
contributions of the treatments cannot be discerned from the
expectations and hope associated with not being blinded. But
because blinding is not possible for most forms of psychotherapy, it
seems reasonable not to do that in pharmacotherapy either when
comparing the effects of the two.
On the other hand, the absence of blinding in a trial in which
both psychotherapy and pharmacotherapy conditions are not
blinded could inﬂuence the outcomes also considerably. Further-
more, such a trial would also require a non-inferiority design,
which would increase the number of participating patients
considerably. So, there is probably no perfect design for trials
comparing psychotherapy and pharmacotherapy, but each design
has its own advantages and disadvantages [47,48].Appendix 1. Standardized regression coefﬁcients of characteristics
pharmacotherapy for adult depression: Multivariate metaregressio
Full model 
Coef. SE 
Placebo condition present (y/n) 0.22 0.15
Combined treatment is included 0.12 0.13
Aimed at adults in general (y/n) 0.25 0.16
Exclusively aimed at dysthymia patients (y/n) 0.18 0.20
Only clinical samples 0.11 0.12
Psychotherapy
CBT Ref.
IPT 0.14 0.12
Other 0.12 0.13
Individual treatment format (y/n) 0.18 0.17
Number of sessions (continuous) 0.02 0.01
Pharmacotherapy
SSRI Ref.
TCA 0.06 0.14
Other 0.27 0.12
Quality (continuous) 0.01 0.04
Conducted in the US (y/n) 0.11 0.12
Constant 0.06 0.25
Please cite this article in press as: Cuijpers P, et al. The effects of blind
adult depression: A meta-analysis. European Psychiatry (2015), httpIt is also important to examine the comparative effects of
psychotherapy and placebo, for example by comparing psycho-
therapy plus placebo with psychotherapy alone or with placebo
alone. Although a few of these studies have been conducted
[38,57], the number is so small that no meta-analysis of these
studies is yet possibly.
This study has several important limitations. First, the quality
of the studies was not optimal and the risk of bias in several
aspects is considerable. Second, the number of studies for
several comparisons was small, resulting in too little power to
examine core questions. Especially, the number of studies in
which a pill placebo condition was included was small. Third, it
was not possible to verify from the papers whether the
treatments (both psychotherapy and pharmacotherapy) were
conducted adequately. This may have inﬂuenced the outcomes
considerably. Fourth, we focused exclusively on depressive
symptoms as outcome. However, other outcomes, such as social
functioning, quality of life, effects of work status, are also highly
relevant, but the number of studies reporting such outcomes
was too low to be included in the analyses. We also did not
consider patient preferences, which typically show that
most patients prefer psychotherapy over pharmacotherapy
[44]. Nor did we examine long-term effects [10]. Finally, it is
the racial and cultural diversity of participants in the trials was
quite limited, so the results may not be generalized to these
groups.
Despite these limitations, we found clear indications that at the
short term, the effects of pharmacotherapy are probably somewhat
better than those of psychotherapy, when both conditions are not
blinded.
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